Skip to content
RecallWatchMedical Device Safety
Class IIOngoingZ-2272-2025

Siemens Healthcare Diagnostics Inc recalls epoc BGEM BUN Test Card [25pk]. Material Number: 10736515.

Siemens Healthcare Diagnostics IncNorwood, MA, United StatesReported Aug 13, 2025 · 11 months ago
Legal News Analyst ·

Reason for recall

Siemens Healthcare Diagnostics Inc. has confirmed that a negative sodium bias may exist in some epoc test card lots. All other analytes are performing as intended. The observed average bias for sodium was -4.4 mmol/L. The maximum bias observed was -14 mmol/L, which occurred at a higher sodium concentration around 150 mmol/L. No positive bias has been observed. Quality Control (QC) fluid may or may not detect the issue depending on the bias magnitude and the frequency of QC testing.

Affected product

Check your device

Enter a lot, serial, REF, or UDI number from your device's label to check it against this recall's listed codes.

Affected products & lots

  • epoc BGEM BUN Test Card [25pk]. Material Number:10736515
    GTIN 00809708121860.
    81 affected lots
    02-25095-3002-25096-3002-25098-3002-25099-3002-25100-3002-25101-3002-25102-3002-25103-30
    +73 more02-25105-3002-25111-3002-25112-3002-25114-3002-25115-3002-25116-3002-25117-3002-25119-3002-25121-3002-25122-3002-25124-3002-25096-4002-25097-4002-25098-4002-25099-4002-25101-4002-25102-4002-25105-4002-25106-4002-25121-4002-25122-4002-25124-4002-25125-4002-25096-5002-25098-5002-25099-5002-25100-5002-25102-5002-25103-5002-25105-5002-25107-5002-25108-5002-25111-5002-25112-5002-25113-5002-25114-5002-25115-5002-25119-5002-25120-5012-25096-6012-25097-6012-25098-6012-25100-6012-25101-6012-25102-6012-25103-6012-25111-6002-25112-6002-25113-6002-25114-6002-25115-6002-25116-6002-25117-6002-25118-6002-25120-6002-25121-6002-25122-6002-25123-6002-25124-6002-25099-7002-25101-7002-25104-7002-25105-7002-25107-7002-25108-7002-25110-7002-25111-7002-25112-7002-25113-7002-25115-7002-25116-7002-25118-7002-25120-70

What the firm is doing

Siemens Healthcare Diagnostics notified consignees via letter on about 07/07/2025. Consignees were instructed to review the letter with the Medical Director to determine the appropriate course of action, including for any previously generated results, if applicable, discard and request a replacement of any affected lots or if your institution does not need to report sodium, you can turn off sodium following the instruction of the owner s manual. Consignees were also instructed to complete and return the Field Correction Effectiveness Check Form included with letter, notify customers if products were further distributed, and to retain this letter with your laboratory records and forward this letter to those who may have received this product at your site.

DistributionShow details

Worldwide distribution - US Nationwide and the countries of Argentina, Austria, Bahrain, Bolivia, Brazil, Canada, Canary Islands, Chile, Croatia, Denmark, Ecuador, Estonia, France, Fren. Polynesia, Germany, Greece, Guatemala, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Jordan, Kazakhstan, Lithuania, Malaysia, Martinique, Mexico, Morocco, Netherlands, New Caledonia, Paraguay, Philippines, Poland, Portugal, Qatar, Rep. Korea (S), Romania, Russian Fed., San Marino, Slovakia, Slovenia, South Africa, Spain, Srilanka, Sweden, Switzerland, Taiwan, Thailand, Turkey, Uganda, Ukraine, Unit.Arab Emir., United Kingdom, Uruguay, Japan.

Class IIWhat this means

Use of the product may cause temporary or medically reversible adverse health consequences.

Sources & references

Taylor Coteus
Legal News Analyst

Taylor Coteus is RecallWatch's Legal News Analyst, covering FDA medical-device enforcement and patient-safety litigation. He reviews every recall against the FDA's official openFDA record before it is published and is responsible for corrections and editorial accuracy.

More Class II recalls